';
Tags Posts tagged with "Brain Injury Association of America"

Brain Injury Association of America

The Brain Injury Association of America (BIAA) will be conducting a virtual Brain Injury Fundamentals course on March 20, 2024 from 1:00 pm – 2:00 pm. The course will provide foundational knowledge about working with individuals who have a brain injury, and is ideal for non-licensed health care professionals, first responders, and support staff.

This course is self-paced, so those who are unable to participate in the in-person course due to scheduling conflicts or other commitments have the opportunity to complete the course with greater flexibility. Please note that while the self-paced option offers 24/7 access for independent learning and development, there is a two-hour live instructor component as well. To participate in the session, please register here.

The Brain Injury Association of America (BIAA) will be offering a free webinar on September 1, 2021 at 3:00pm. The webinar, titled “The Cutting Edge of Brain Injury Evaluation in the ED: Using Biomarkers for Objective Assessment of Suspected Mild Traumatic Brain Injury (mTBI),” will provide the latest research into blood-based biomarkers and their potential to predict the absence of intracranial injury. Jeff Bazarian, M.D., M.P.H., Paul Jarvis, M.D., and Jesse M. Pines, M.D. will also provide information on how two proteins, Ubiquitin C-terminal hydrolase-L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP), have emerged as promising biomarkers that can be used in conjunction with other clinical information to aid in the evaluation of suspected mTBI patients in the Emergency Department (ED).

The deadline to register is August 31, 2021.

0 1379

The Brain Injury Association of America (BIAA) recently released information about a Traumatic Brain Injury (TBI) Behavior study. The researchers of the study are looking for individuals that have experienced a TBI and are showing symptoms of aggression, agitation, and irritability. The results of the study will provide more information (safety and effectiveness) about an investigational drug and whether it could one day be used to help treat behavioral problems due to TBI.